{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T05:52:21Z","timestamp":1792043541359,"version":"4.4.0"},"reference-count":74,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1016\/j.ygyno.2011.01.029","type":"journal-article","created":{"date-parts":[[2011,2,21]],"date-time":"2011-02-21T15:21:48Z","timestamp":1298301708000},"page":"514-521","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Cost\u2013consequences evaluation between bivalent and quadrivalent HPV vaccines in Italy: The potential impact of different cross-protection profiles"],"prefix":"10.1016","volume":"121","author":[{"given":"S.","family":"Capri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Gasparini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Panatto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Demarteau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2011.01.029_bb0005","author":"Ferlay"},{"issue":"2","key":"10.1016\/j.ygyno.2011.01.029_bb0010","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1177\/030089160909500203","article-title":"Incidence of invasive cervical cancer and direct costs associated with its management in Italy","volume":"95","author":"Ricciardi","year":"2009","journal-title":"Tumori"},{"issue":"1\u20132","key":"10.1016\/j.ygyno.2011.01.029_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1386-6532(00)00125-6","article-title":"Human papillomavirus and cancer: the epidemiological evidence","volume":"19","author":"Munoz","year":"2000","journal-title":"J Clin Virol"},{"issue":"Supplement 10","key":"10.1016\/j.ygyno.2011.01.029_bb0020","doi-asserted-by":"crossref","first-page":"K1","DOI":"10.1016\/j.vaccine.2008.05.064","article-title":"Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia","volume":"26","author":"Bosch","year":"2008","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.ygyno.2011.01.029_bb0025","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1158\/1055-9965.EPI-04-0812","article-title":"Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer","volume":"14","author":"Clifford","year":"2005","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"3","key":"10.1016\/j.ygyno.2011.01.029_bb0030","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1002\/ijc.22527","article-title":"Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update","volume":"121","author":"Smith","year":"2007","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2011.01.029_bb0035","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F","article-title":"Human papillomavirus is a necessary cause of invasive cervical cancer worldwide","volume":"189","author":"Walboomers","year":"1999","journal-title":"J Pathol"},{"issue":"10","key":"10.1016\/j.ygyno.2011.01.029_bb0040","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1128\/JCM.37.10.3316-3322.1999","article-title":"Detection of multiple human papillomavirus types in condylomata acuminata lesions from otherwise healthy and immunosuppressed patients","volume":"37","author":"Brown","year":"1999","journal-title":"J Clin Microbiol"},{"issue":"12","key":"10.1016\/j.ygyno.2011.01.029_bb0045","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1086\/498164","article-title":"Randomized controlled trial of an adjuvanted human papillomavirus (HPV) type 6 L2E7 vaccine: infection of external anogenital warts with multiple HPV types and failure of therapeutic vaccination","volume":"192","author":"Vandepapeliere","year":"2005","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.ygyno.2011.01.029_bb0050","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ejogrb.2003.11.026","article-title":"Gynaecological cancers in Umbria (Italy): trends of incidence, mortality and survival, 1978\u20131998","volume":"115","author":"Minelli","year":"2004","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"7188","key":"10.1016\/j.ygyno.2011.01.029_bb0055","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1136\/bmj.318.7188.904","article-title":"Effect of screening on incidence of and mortality from cancer of cervix in England: evaluation based on routinely collected statistics","volume":"318","author":"Quinn","year":"1999","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.ygyno.2011.01.029_bb0060","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1158\/1055-9965.EPI-04-0569","article-title":"Trends in cervical squamous cell carcinoma incidence in 13 European countries: changing risk and the effects of screening","volume":"14","author":"Bray","year":"2005","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"127","key":"10.1016\/j.ygyno.2011.01.029_bb0065","author":"Ministero della Sanita","year":"1996","journal-title":"Gazz Ufficiale"},{"issue":"1 Suppl 3","key":"10.1016\/j.ygyno.2011.01.029_bb0070","first-page":"27","article-title":"Activity level and process indicators of organised programmes for cervical cancer screening in Italy","volume":"30","author":"Ronco","year":"2006","journal-title":"Epidemiol Prev"},{"key":"10.1016\/j.ygyno.2011.01.029_bb0075","series-title":"Il sistema di sorveglianza sui Progressi delle Aziende Sanitarie per la Salute in Italia (Passi) dall'ascolto dei cittadini alle azioni di prevenzione: Rapporto Nazionale 2008","year":"2009"},{"issue":"33\u201334","key":"10.1016\/j.ygyno.2011.01.029_bb0080","doi-asserted-by":"crossref","first-page":"5937","DOI":"10.1016\/j.vaccine.2006.06.005","article-title":"Enhanced humoral and memory B cellular immunity using HPV16\/18L1 VLP vaccine formulated with the MPL\/aluminium salt combination (AS04) compared to aluminium salt only","volume":"24","author":"Giannini","year":"2006","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.ygyno.2011.01.029_bb0085","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S1470-2045(09)70096-8","article-title":"A review of human carcinogens\u2014Part B: Biological agents","volume":"10","author":"Bouvard","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ygyno.2011.01.029_bb0090","series-title":"Human Papillomaviruses","author":"IARC Working Group on the Evaluation of Carcinogenic Risks to Humans","year":"2007"},{"issue":"5","key":"10.1016\/j.ygyno.2011.01.029_bb0095","doi-asserted-by":"crossref","first-page":"407","DOI":"10.4161\/hv.6.5.11023","article-title":"Molecular and structural characterization of the L1 virus-like particles that are used as vaccine antigens in Cervarix, the AS04-adjuvanted HPV-16 and -18 cervical cancer vaccine","volume":"6","author":"Deschuyteneer","year":"2010","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.ygyno.2011.01.029_bb0100","author":"EMEA"},{"issue":"10","key":"10.1016\/j.ygyno.2011.01.029_bb0105","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1002\/jps.20696","article-title":"Disassembly and reassembly of yeast-derived recombinant human papillomavirus virus-like particles (HPV VLPs)","volume":"95","author":"Mach","year":"2006","journal-title":"J Pharm Sci"},{"issue":"9686","key":"10.1016\/j.ygyno.2011.01.029_bb0110","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0140-6736(09)61248-4","article-title":"Efficacy of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women","volume":"374","author":"Paavonen","year":"2009","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ygyno.2011.01.029_bb0115","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/sj.bjc.6603469","article-title":"High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6\/11\/16\/18 L1 virus-like particle vaccine through 5years of follow-up","volume":"95","author":"Villa","year":"2006","journal-title":"Br J Cancer"},{"issue":"7","key":"10.1016\/j.ygyno.2011.01.029_bb0120","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1086\/597307","article-title":"The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16\u201326years","volume":"199","author":"Brown","year":"2009","journal-title":"J Infect Dis"},{"issue":"10","key":"10.1016\/j.ygyno.2011.01.029_bb0125","doi-asserted-by":"crossref","first-page":"702","DOI":"10.4161\/hv.5.10.9518","article-title":"Comparison of the immunogenicity and safety of Cervarix(TM) and Gardasil(R) human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18\u201345years","volume":"5","author":"Einstein","year":"2009","journal-title":"Hum Vaccin"},{"issue":"12","key":"10.1016\/j.ygyno.2011.01.029_bb0130","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1586\/erv.09.123","article-title":"Currently approved prophylactic HPV vaccines","volume":"8","author":"Harper","year":"2009","journal-title":"Expert Rev Vaccin"},{"key":"10.1016\/j.ygyno.2011.01.029_bb0135","doi-asserted-by":"crossref","first-page":"b1147","DOI":"10.1136\/bmj.b1147","article-title":"Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews","volume":"338","author":"Song","year":"2009","journal-title":"BMJ"},{"issue":"3 Suppl. 1","key":"10.1016\/j.ygyno.2011.01.029_bb0140","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/j.ygyno.2008.06.027","article-title":"A review of cross-protection against oncogenic HPV by an HPV-16\/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention","volume":"110","author":"Jenkins","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.01.029_bb0145","series-title":"Abstract n\u00b0 O-29.01 Presented at the 25th International Papillomavirus Conference, May 8\u201314, Malm\u00f6, Sweden","article-title":"Cross-protection efficacy of Cervarix(tm) against oncogenic HPV types beyond HPV-16\/18","author":"Skinner","year":"2009"},{"issue":"3","key":"10.1016\/j.ygyno.2011.01.029_bb0150","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1517\/14712591003601944","article-title":"HPV vaccine: Cervarix","volume":"10","author":"Szarewski","year":"2010","journal-title":"Expert Opin Biol Ther"},{"issue":"9574","key":"10.1016\/j.ygyno.2011.01.029_bb0155","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/S0140-6736(07)60777-6","article-title":"Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials","volume":"369","author":"Joura","year":"2007","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ygyno.2011.01.029_bb0160","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2217\/14750708.5.3.305","article-title":"Evaluating the potential benefits of universal worldwide human papillomavirus vaccination","volume":"5","author":"Bosch","year":"2008","journal-title":"Therapy"},{"issue":"1","key":"10.1016\/j.ygyno.2011.01.029_bb0165","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3111\/13696990801961611","article-title":"Economic burden associated with the management of cervical cancer, cervical dysplasia and genital warts in Belgium","volume":"11","author":"Annemans","year":"2008","journal-title":"J Med Econ"},{"key":"10.1016\/j.ygyno.2011.01.029_bb0170","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/1471-2334-8-76","article-title":"Estimation of the incidence of genital warts and the cost of illness in Germany: a cross-sectional study","volume":"8","author":"Hillemanns","year":"2008","journal-title":"BMC Infect Dis"},{"issue":"8\u20139","key":"10.1016\/j.ygyno.2011.01.029_bb0175","first-page":"991","article-title":"Incidence and management of condylomata acuminata by French general physicians","volume":"129","author":"Lukasiewicz","year":"2002","journal-title":"Ann Dermatol V\u00e9n\u00e9r\u00e9ol"},{"issue":"2","key":"10.1016\/j.ygyno.2011.01.029_bb0180","first-page":"107","article-title":"Anogenital warts incidence, medical management and costs in women consulting gynaecologists in France","volume":"35","author":"Monsonego","year":"2007","journal-title":"Gyn\u00e9col Obst\u00e9t Fertil"},{"key":"10.1016\/j.ygyno.2011.01.029_bb0185","author":"WHO\/ICO"},{"issue":"19","key":"10.1016\/j.ygyno.2011.01.029_bb0190","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa061741","article-title":"Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions","volume":"356","author":"The FUTURE II Study Group","year":"2007","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.ygyno.2011.01.029_bb0195","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1056\/NEJMoa061760","article-title":"Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases","volume":"356","author":"Garland","year":"2007","journal-title":"N Engl J Med"},{"issue":"9447","key":"10.1016\/j.ygyno.2011.01.029_bb0200","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0140-6736(04)17398-4","article-title":"Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial","volume":"364","author":"Harper","year":"2004","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ygyno.2011.01.029_bb0205","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/jnci\/djp534","article-title":"Impact of human papillomavirus (HPV)-6\/11\/16\/18 vaccine on all HPV-associated genital diseases in young women","volume":"102","author":"Munoz","year":"2010","journal-title":"J Natl Cancer Inst"},{"issue":"3 Suppl.1","key":"10.1016\/j.ygyno.2011.01.029_bb0210","first-page":"S10","volume":"108","author":"Huh","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.01.029_bb0215","series-title":"Abstract n\u00b0 A-171-0004-01446 Presented at the 16th International Meeting of the European Society for Gynaecological Oncology (ESGO), 11\u201314 Oct, Belgrade, Serbia","article-title":"Efficacy of the HPV-16\/18 AS04-adjuvanted vaccine against abnormal cytology and low-grade histopathological lesions in an oncogenic HPV-na\u00efve population","author":"Tjalma","year":"2009"},{"issue":"2 Suppl.1","key":"10.1016\/j.ygyno.2011.01.029_bb0220","first-page":"55","article-title":"Capitolo 6: Impatto clinico ed economico della vaccinazione anti-HPV","volume":"4","author":"Capri","year":"2007","journal-title":"Ital J Public Health"},{"issue":"2 Suppl.1","key":"10.1016\/j.ygyno.2011.01.029_bb0225","first-page":"22","article-title":"Capitolo 3: Analisi dei costi del ricorso alle risorse sanitaire pe rla prevenzione e il trattamento del carcinoma della cervice uterina","volume":"4","author":"Marocco","year":"2007","journal-title":"Ital J Public Health"},{"key":"10.1016\/j.ygyno.2011.01.029_bb0230","author":"L'Istituto nazionale di statistica"},{"issue":"11","key":"10.1016\/j.ygyno.2011.01.029_bb0235","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1185\/03007990802485694","article-title":"Treatment patterns and associated costs for genital warts in Italy","volume":"24","author":"Merito","year":"2008","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"10.1016\/j.ygyno.2011.01.029_bb0240","first-page":"183","article-title":"Epidemiologia e costi dei condilomi ano-genitali in Italia: revisione delle evidenze disponibili","volume":"9","author":"Bamfi","year":"2008","journal-title":"Farmeconomia Percorsi Terapeut"},{"issue":"1","key":"10.1016\/j.ygyno.2011.01.029_bb0245","first-page":"33","article-title":"A new approach to estimate genital warts incidence and prevalence in the Italian general population","volume":"20","author":"Vittori","year":"2008","journal-title":"Int J Gynaecol Obstet"},{"issue":"7","key":"10.1016\/j.ygyno.2011.01.029_bb0250","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1002\/ijc.24116","article-title":"Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis","volume":"124","author":"De Vuyst","year":"2009","journal-title":"Int J Cancer"},{"issue":"10 Suppl","key":"10.1016\/j.ygyno.2011.01.029_bb0255","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1002\/cncr.23764","article-title":"HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women","volume":"113","author":"Gillison","year":"2008","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.ygyno.2011.01.029_bb0260","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1097\/01.AOG.0000245786.86267.80","article-title":"Effect of human papillomavirus vaccines on vulvar, vaginal, and anal intraepithelial lesions and vulvar cancer","volume":"108","author":"Hampl","year":"2006","journal-title":"Obstet Gynecol"},{"issue":"10 Suppl","key":"10.1016\/j.ygyno.2011.01.029_bb0265","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1002\/cncr.23758","article-title":"Using population-based cancer registry data to assess the burden of human papillomavirus-associated cancers in the United States: overview of methods","volume":"113","author":"Watson","year":"2008","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.ygyno.2011.01.029_bb0270","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1158\/1055-9965.EPI-07-2922","article-title":"A systematic review of the prevalence and attribution of human papillomavirus types among cervical, vaginal, and vulvar precancers and cancers in the United States","volume":"17","author":"Insinga","year":"2008","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"17","key":"10.1016\/j.ygyno.2011.01.029_bb0275","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1093\/jnci\/djg037","article-title":"Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia","volume":"95","author":"Schlecht","year":"2003","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.ygyno.2011.01.029_bb0280","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/ijc.20846","article-title":"Natural history and screening model for high-risk human papillomavirus infection, neoplasia and cervical cancer in the Netherlands","volume":"115","author":"Berkhof","year":"2005","journal-title":"Int J Cancer"},{"issue":"6","key":"10.1016\/j.ygyno.2011.01.029_bb0285","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1365-2303.1990.tb00369.x","article-title":"Carcinoma in situ of the cervix and its malignant potential. A lesson from New Zealand","volume":"1","author":"Chang","year":"1990","journal-title":"Cytopathology"},{"issue":"7526","key":"10.1016\/j.ygyno.2011.01.029_bb0290","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1136\/bmj.38663.459039.7C","article-title":"Risk of cervical and other cancers after treatment of cervical intraepithelial neoplasia: retrospective cohort study","volume":"331","author":"Kalliala","year":"2005","journal-title":"BMJ"},{"issue":"14","key":"10.1016\/j.ygyno.2011.01.029_bb0295","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/jnci\/dji187","article-title":"The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice","volume":"97","author":"Khan","year":"2005","journal-title":"J Natl Cancer Inst"},{"issue":"4 Pt 2","key":"10.1016\/j.ygyno.2011.01.029_bb0300","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/S0002-9378(96)70011-X","article-title":"Natural history of cervical neoplasia: overview and update","volume":"175","author":"Kiviat","year":"1996","journal-title":"Am J Obstet Gynecol"},{"issue":"5","key":"10.1016\/j.ygyno.2011.01.029_bb0305","first-page":"535","article-title":"Screening for cervical cancer: should we test for infection with high-risk HPV?","volume":"163","author":"Meijer","year":"2000","journal-title":"CMAJ"},{"issue":"2","key":"10.1016\/j.ygyno.2011.01.029_bb0310","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/00004347-199304000-00018","article-title":"Natural history of cervical intraepithelial neoplasia: a critical review","volume":"12","author":"Ostor","year":"1993","journal-title":"Int J Gynecol Pathol"},{"issue":"31","key":"10.1016\/j.ygyno.2011.01.029_bb0315","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/oxfordjournals.jncimonographs.a003476","article-title":"Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia","author":"Schiffman","year":"2003","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"2","key":"10.1016\/j.ygyno.2011.01.029_bb0320","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/path.1866","article-title":"HPV-mediated cervical carcinogenesis: concepts and clinical implications","volume":"208","author":"Snijders","year":"2006","journal-title":"J Pathol"},{"issue":"9222","key":"10.1016\/j.ygyno.2011.01.029_bb0325","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1016\/S0140-6736(00)02402-8","article-title":"Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: a nested case\u2013control study","volume":"355","author":"Ylitalo","year":"2000","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1016\/j.ygyno.2011.01.029_bb0330","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1093\/clinids\/20.Supplement_1.S91","article-title":"Human papillomavirus infection and genital warts: update on epidemiology and treatment","volume":"20","author":"Stone","year":"1995","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.ygyno.2011.01.029_bb0335","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1086\/427557","article-title":"Development and duration of human papillomavirus lesions, after initial infection","volume":"191","author":"Winer","year":"2005","journal-title":"J Infect Dis"},{"issue":"9706","key":"10.1016\/j.ygyno.2011.01.029_bb0340","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/S0140-6736(09)61567-1","article-title":"Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4years","volume":"374","author":"Romanowski","year":"2009","journal-title":"Lancet"},{"issue":"26","key":"10.1016\/j.ygyno.2011.01.029_bb0345","doi-asserted-by":"crossref","first-page":"4931","DOI":"10.1016\/j.vaccine.2007.03.049","article-title":"Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6\/11\/16\/18 L1 virus-like particle (VLP) vaccine","volume":"25","author":"Olsson","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.ygyno.2011.01.029_bb0350","series-title":"Abstract Presented at 28th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID), May 4\u20138, Nice, France","article-title":"Sustained immunogenicity and efficacy of the HPV-16\/18 AS04 adjuvanted vaccine: follow-up to 8.4 years","author":"Roteli-Martins","year":"2010"},{"issue":"21","key":"10.1016\/j.ygyno.2011.01.029_bb0355","doi-asserted-by":"crossref","first-page":"4324","DOI":"10.1016\/j.vaccine.2007.02.069","article-title":"Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine","volume":"25","author":"Fraser","year":"2007","journal-title":"Vaccine"},{"issue":"3 Suppl 1","key":"10.1016\/j.ygyno.2011.01.029_bb0360","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.ygyno.2009.01.011","article-title":"Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses","volume":"115","author":"David","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.01.029_bb0365","doi-asserted-by":"crossref","DOI":"10.1086\/597071","article-title":"Natural History of Genital Warts: Analysis of the Placebo Arm of 2 Randomized Phase III Trials of a Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Vaccine","author":"Garland","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ygyno.2011.01.029_bb0370","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1471-2458-9-71","article-title":"Epidemiology and costs of cervical cancer screening and cervical dysplasia in Italy","volume":"9","author":"Giorgi Rossi","year":"2009","journal-title":"BMC Public Health"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825811000734?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825811000734?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:31:55Z","timestamp":1758771115000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825811000734"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":74,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["S0090825811000734"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2011.01.029","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2011,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost\u2013consequences evaluation between bivalent and quadrivalent HPV vaccines in Italy: The potential impact of different cross-protection profiles","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2011.01.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}